{
    "clinical_study": {
        "@rank": "156546", 
        "arm_group": {
            "arm_group_label": "Zirconium silicate", 
            "arm_group_type": "Experimental", 
            "description": "Open label oral administration of zirconium silicate 10g once daily for 2 months."
        }, 
        "brief_summary": {
            "textblock": "Subjects who completed the Double-blind Randomized Maintenance Phase (DBRMP) Study Day 29\n      visit in ZS-004 and have an i-STAT potassium value that is 3.5 to 6.2 mmol/l inclusive or\n      who discontinued during ZS-004 due to hypo- or hyperkalemia in the DBRMP and have a mean\n      i-STAT potassium value from two consecutive measurements at 0 and 60 minutes on Acute Phase\n      Day 1/Maintenance Phase Day 1 that is 3.5 to 6.2 mmol/l inclusive may have the option to\n      participate in ZS-004E. Subjects who discontinued from study ZS-004 due to any other reasons\n      (e.g. adverse events, poor compliance, investigator decision) will not be entered into study\n      ZS-004E. All subjects who continue into the extension study must begin dosing within two (2)\n      days after the last dose of investigational product in ZS-004."
        }, 
        "brief_title": "Open-label Dosing of ZS 10g qd for 60 Days to Extend Study ZS-004, Safety & Efficacy of ZS (Zirconium Silicate) in Hyperkalemia.", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hyperkalemia", 
        "condition_browse": {
            "mesh_term": "Hyperkalemia"
        }, 
        "detailed_description": {
            "textblock": "All subjects with i-STAT potassium values between 3.5-5.5 mmol/l, inclusive at the ZS-004\n      DBRMP Study Day 29 visit, who continue directly into the open-label extension study ZS-004E,\n      will enter the Maintenance Phase (MP) and start on open-label ZS at a dose of 10g qd. All\n      subjects with i-STAT potassium values > 5.5 mmol/l at the ZS-004 DBRMP Study Day 29 visit\n      will undergo an acute treatment phase (AP) where they will receive ZS 10g three times a day\n      (tid) for 24 (3 doses) or 48 hours (6 doses). If the subject's i-STAT potassium is between\n      3.5-5.0 mmol/l, inclusive after 24 (AP Study Day 2) or 48 hours (AP Study Day 3), the\n      subject will enter the MP at a starting dose of 10g qd.\n\n      For subjects who discontinued during ZS-004 DBRMP due to hypo- or hyperkalemia baseline\n      potassium values will be determined within 1 day of administration of the first dose in the\n      ZS-004E extension study by taking two (2) consecutive i-STAT potassium measurements at 0 and\n      60 minutes (\u00b1 10 minutes). If the mean i-STAT value is between 3.5 - 5.5 mmol/l, inclusive,\n      the subject will enter directly into the MP and receive 10g ZS qd; if the mean i-STAT\n      potassium value is > 5.5 mmol/l, the subject will enter the AP. If i-STAT potassium values\n      are still >5.0 mmol/l on the morning of AP Study Day 3, subjects will not enter the MP but\n      will be referred to their normal health care provider for standard of care.\n\n      If the i-STAT potassium value increases above 5.5 mmol/l during the MP with treatment at 10g\n      qd, the dose can be increased to15g qd. Conversely, if S-K decreases to between 3.0-3.4\n      mmol/l, inclusive, the dose of ZS can be decreased in 5g qd, decrements. If a subject is on\n      a 5g qd dose and still develops blood potassium i-STAT values between 3.0 - 3.4mmol,\n      inclusive the dose can be reduced to 5g every other day.\n\n      Subjects will receive up to 2 months of treatment with open-label ZS."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Provision of written informed consent.\n\n          -  Completed the ZS-004 DBRMP Study Day 29 visit or discontinued study ZS-004 during the\n             DBRMP due to hypo- or hyperkalemia and able to start dosing in ZS-004E within two (2)\n             days after the last dose of Investigational product in ZS-004.\n\n          -  Subject must have an i-STAT potassium value that is 3.5 to 6.2 mmol/l inclusive at\n             the ZS-004 DBRMP Study Day 29 visit or a mean i-STAT potassium value from two\n             consecutive measurements at 0 and 60 minutes on Acute Phase Day 1/Maintenance Phase\n             Day 1 that is 3.5 to 6.2 mmol/l inclusive if the subject discontinued study ZS-004\n             during the DBRMP due to hypo- or hyperkalemia .\n\n        Exclusion Criteria:\n\n          -  Pseudohyperkalemia signs and symptoms, such as excessive fist clenching hemolyzed\n             blood specimen, history of severe leukocytosis or thrombocytosis.\n\n          -  Subjects who received alternative treatment for hyperkalemia while participating in\n             study ZS-004.\n\n          -  Subjects with a life expectancy of less than 3 months.\n\n          -  Subjects who are severely physically or mentally incapacitated and who in the opinion\n             of investigator are unable to perform the subjects' tasks associated with the\n             protocol.\n\n          -  Women who are pregnant, lactating, or planning to become pregnant.\n\n          -  Subjects with diabetic ketoacidosis.\n\n          -  Presence of any condition which, in the opinion of the investigator, places the\n             subject at undue risk or potentially jeopardizes the quality of the data to be\n             generated.\n\n          -  Known hypersensitivity or previous anaphylaxis to ZS or to components thereof.\n\n          -  Treatment with a drug or device other than ZS within the last 30 days that has not\n             received regulatory approval at the time of study entry.\n\n          -  Subjects with cardiac arrhythmias that require immediate treatment.\n\n          -  Subjects on dialysis."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 3, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02107092", 
            "org_study_id": "ZS-004E"
        }, 
        "intervention": {
            "arm_group_label": "Zirconium silicate", 
            "description": "Oral 10g once daily with breakfast for 2 months.", 
            "intervention_name": "Zirconium silicate", 
            "intervention_type": "Drug", 
            "other_name": "ZS"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Anniston", 
                        "country": "United States", 
                        "state": "Alabama"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tempe", 
                        "country": "United States", 
                        "state": "Arizona"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paramount", 
                        "country": "United States", 
                        "state": "California"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Atlantis", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brandon", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Edgewater", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami Lakes", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Smyrna Beach", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Summerfield", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Winter Park", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sumter", 
                        "country": "United States", 
                        "state": "South Carolina"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gosford", 
                        "country": "Australia", 
                        "state": "New South Wales"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Woolloongabba", 
                        "country": "Australia", 
                        "state": "Queensland"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Heidelberg", 
                        "country": "Australia", 
                        "state": "Victoria"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Melbourne", 
                        "country": "Australia", 
                        "state": "Victoria"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Parkville", 
                        "country": "Australia", 
                        "state": "Victoria"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Meyerspark", 
                        "country": "South Africa"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Port Elizabeth", 
                        "country": "South Africa"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Somerset West", 
                        "country": "South Africa"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Australia", 
                "South Africa"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "Open-label Extension to Study ZS-004 [Phase 3 Multicenter, Multi-phase, Multi-dose, Prospective, Randomized, Double-blind, Placebo-controlled Maintenance Study of Safety Efficacy of ZS (Zirconium Silicate) in Hyperkalemia.]", 
        "overall_contact": {
            "email": "hrasmussen@zspharma.com", 
            "last_name": "Henrik Rasmussen, MD, PhD", 
            "phone": "443-699-5230"
        }, 
        "overall_official": {
            "affiliation": "ZS Pharma, Inc.", 
            "last_name": "Henrik Rasmussen, MD, PhD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Efficacy endpoints will include the proportion of subjects who achieve and maintain normokalemia (defined as serum potassium [S-K] between 3.5-5.0 mmol/l, inclusive) throughout the 1 and 2 months of treatment as well as the proportion of subjects who can achieve and maintain S-K levels between 3.5 and 5.5 mmol/l inclusive, throughout the 1 and 2 months of treatment.", 
            "measure": "Maintenance of serum potassium within normal range (3.5 5.0 mmol/l) with once daily ZS for 2 months after establishment of normokalemia in prior ZS-004 study, or after an additional 48-hour treatment with 10g ZS three times daily.", 
            "safety_issue": "Yes", 
            "time_frame": "2 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02107092"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "ZS Pharma, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "ZS Pharma, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}